Quest Diagnostics Inc (NYSE:DGX) has earned a consensus rating of “Hold” from the twenty-three analysts that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and seven have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $104.92.
Several research analysts have weighed in on DGX shares. KeyCorp reiterated a “hold” rating on shares of Quest Diagnostics in a report on Friday, October 27th. ValuEngine upgraded Quest Diagnostics from a “hold” rating to a “buy” rating in a report on Friday, September 1st. Wells Fargo & Company lowered their price target on Quest Diagnostics from $88.00 to $86.00 and set a “market perform” rating on the stock in a research report on Friday, October 20th. Goldman Sachs Group downgraded Quest Diagnostics from a “conviction-buy” rating to a “buy” rating and lowered their price target for the stock from $121.00 to $113.00 in a research report on Tuesday, October 10th. Finally, Canaccord Genuity boosted their price objective on Quest Diagnostics from $100.00 to $105.00 and gave the stock a “buy” rating in a report on Thursday, October 26th.
In related news, Chairman Stephen H. Rusckowski sold 59,235 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $108.16, for a total value of $6,406,857.60. Following the completion of the sale, the chairman now directly owns 220,049 shares in the company, valued at $23,800,499.84. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 1.75% of the company’s stock.
Quest Diagnostics (NYSE:DGX) traded up $0.47 during trading hours on Monday, hitting $97.09. The stock had a trading volume of 764,400 shares, compared to its average volume of 1,022,508. Quest Diagnostics has a 1-year low of $89.46 and a 1-year high of $112.96. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.47 and a quick ratio of 1.37. The company has a market cap of $13,230.00, a price-to-earnings ratio of 17.40, a P/E/G ratio of 2.02 and a beta of 0.60.
Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings results on Thursday, October 19th. The medical research company reported $1.39 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.35 by $0.04. The business had revenue of $1.93 billion for the quarter, compared to analyst estimates of $1.92 billion. Quest Diagnostics had a return on equity of 15.53% and a net margin of 8.82%. The firm’s revenue was up 2.4% on a year-over-year basis. During the same period last year, the company earned $1.37 EPS. sell-side analysts predict that Quest Diagnostics will post 5.65 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 24th. Investors of record on Tuesday, January 9th will be paid a $0.45 dividend. This represents a $1.80 annualized dividend and a dividend yield of 1.85%. The ex-dividend date of this dividend is Monday, January 8th. Quest Diagnostics’s dividend payout ratio (DPR) is currently 37.50%.
Quest Diagnostics Company Profile
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).
Receive News & Ratings for Quest Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Inc and related companies with MarketBeat.com's FREE daily email newsletter.